Phase II High-Dose Cyclophosphamide for Multiple Sclerosis

Withdrawn before enrolling · Phase 2

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to determine what percentage of patients receiving high-dose Cyclophosphamide may experience a halt in the worsening of their disease or experience improvement of their disease and for how long the benefit may last.

Key facts

Study ID
NCT00296205
Run by
Stony Brook University
People needed
25
Starts
2003-10-01
Expected to finish
2006-02-01
Last updated by the study team
2009-07-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.